Developing a new method for delivering cancer vaccines
Official title: Controlled Antigen Delivery for Prophylactic Cancer Vaccination
Funded at Massachusetts Institute of Technology · NIH-11088942 · Data updated 2026-11-12
This study is testing a new way to deliver cancer treatments directly to tumors using a special gel, which could make the treatments work better and cause fewer side effects for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts Institute of Technology NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | September 1, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $97,672 |
| NIH project number | 5K00CA284262-03 |
| Project ID | NIH-11088942 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who are diagnosed with solid tumors and may benefit from localized cancer therapies.
✕Less likely to help
Patients with cancers that are not solid tumors or those who are not eligible for localized treatment approaches may not benefit from this research.
What this research studies
This research focuses on creating a peptide-based hydrogel platform that allows for the targeted delivery of cancer treatments directly to tumors. By using this innovative approach, the goal is to enhance the effectiveness of existing cancer therapies while reducing harmful side effects that often affect patients' quality of life. The study aims to utilize boronic acid-containing small molecule drugs, which have shown promise in treating certain cancers, and deliver them locally to maximize their impact. Patients may benefit from a more effective treatment with fewer systemic toxicities.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments with reduced side effects for patients.
How similar studies have gone: Previous research has shown promise in using localized drug delivery systems for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
-
Massachusetts Institute of Technology
Cambridge, United States Active
Researchers
- Principal investigator: Pogostin, Brett — Massachusetts Institute of Technology
- Study coordinator: Pogostin, Brett
Related research
Other NIH-funded projects on the same topics.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
Respiratory pathogen–specific T cell signatures after vaccination, infection, and treatment
A research effort to map how immune T cells respond to respiratory infections and vaccines, with potential to guide better vaccines and treatments for conditions like covid-19 and pertussis.
-
Malaria vaccine and infection: how the body’s early and later immune responses relate to protection
Researchers are studying how people’s immune systems respond to the malaria pre-erythrocytic stage, whether after vaccination or infection, to identify which responses are linked to protection.
-
Spatially responsive mass vaccination for urban rabies
A new plan uses data and maps to place vaccination sites where they’re most needed in cities, aiming to boost rabies vaccination for both people and dogs.
-
Spatially responsive mass vaccination for urban rabies
A project tests smarter placement of vaccination sites to increase mass canine rabies vaccination in cities.
-
Vaccine failure after Covid-19 vaccination in older adults
This project follows vaccinated older adults to understand who among them still gets Covid-19 and what factors make those outcomes worse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.